Speaker Date Topic
Orrin Mahoney, Rotary Sep 22, 2020
An update on the Rotary Foundation, with a focus on the amazing work that District 5170 Clubs do
An update on the Rotary Foundation, with a focus on the amazing work that District 5170 Clubs do

Orrin Mahoney is a long time resident of Cupertino, California. After graduating from Carnegie-Mellon University in 1967, he came to California to work at Hewlett-Packard and received a Master’s degree from Stanford while working there. After a 35 year management career at HP, he retired and devoted his time to community activities. He is a former member of the Cupertino City Council, and has served twice as Mayor.

In addition to many other community groups, he is an active member and past president of the Rotary Club of Cupertino. As part of the Club’s International Service activities, he has participated in 11 project trips to Mexico, China, India, and Central and South America. He was District 5170 District Governor in 2017-2018, and is the District TRF Chair this year.

Monica Gandhi, MD, UCSF Professor of Medicine Oct 06, 2020
Masks Protect You and Others from Covid
Masks Protect You and Others from Covid

Monica Gandhi MD, MPH is Professor of Medicine and Associate Division Chief (Clinical Operations/Education) of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/ San Francisco General Hospital. 

As the COVID-19 pandemic has received a great deal of attention, we'll discuss for one of the first times the hypothesis that universal masking reduces the “inoculum” or dose of the virus for the mask-wearer, leading to more mild and asymptomatic infection manifestations.  Masks, depending on type, filter out the majority of viral particles, but not all. We first discuss the near-century old literature around the viral inoculum and severity of disease We will then include examples of rising rates of asymptomatic infection with population-level masking, including in closed settings (e.g. cruise ships), outbreaks, and countrieswith and without universal masking. Asymptomatic infections may be harmful for spread but could actually be beneficial if they lead to higher rates of exposure. Exposing society to SARS-CoV-2 without the unacceptable consequences of severe illness with public masking could lead to greater community-level immunity and slower spread as we await a vaccine

Dr. Joel Ernst, UCSF Oct 13, 2020
“COVID Treatments and Vaccines” What do we need and What do we have to beat the pandemic
“COVID Treatments and Vaccines”  What do we need and What do we have to beat the pandemic

Joel Ernst trained in Internal Medicine, Infectious Diseases, and in Hematology and Oncology at the University of California, San Francisco.  He joined the faculty at UCSF where he established a research program in host-pathogen interactions and immunity, and cared for patients with infectious diseases, including the earliest AIDS patients, at San Francisco General Hospital.  He was recruited to the NYU School of Medicine in 2003, where he was Director of the Division of Infectious Diseases and Immunology as well as Director of the Graduate Program in Immunology and Inflammation, and Professor of Medicine, Pathology, and Microbiology.  In 2018, he was recruited to UCSF where he is Professor of Medicine and Chief of the Division of Experimental Medicine. 

COVID-19 is a global pandemic that has changed every aspect of life for billions of people.  The cause is an RNA virus, termed SARS-CoV-2, that is transmitted by the respiratory route and that leads to diverse clinical consequences.  Global control of COVID-19 will depend on development and deployment of vaccines that are safe, able to be produced rapidly in hundreds of millions (or billions) of doses, and inexpensive.  Likewise, preventing complications and mortality requires development and clinical use of drugs that control the infection and that prevent and treat the complications.  This presentation will feature general information about the infection, general principles of antiviral and anti-inflammatory drugs, and principles of vaccine development, testing, and implementation.  It will also provide a summary of the present status of drug and vaccine development for COVID-19.